|
|
Vaccine Detail
|
MCMV-TRP2 |
| Vaccine Information |
- Vaccine Name: MCMV-TRP2
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007638
- Type: Cytomegalovirus-based cancer vaccine
- Status: Research
- Antigen: TRP2
- Preparation: We expressed an unmodified melanoma antigen, mouse tyrosinase-related protein 2 (TRP2), in mouse cytomegalovirus (MCMV). Prophylactic vaccination of the mice with a single dose of MCMV-TRP2 induced rejection of B16 melanoma challenge; therapeutic vaccination with MCMV-TRP2 prolonged the survival of the mice challenged with B16 cells (Xu et al., 2013).
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Mouse Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: T cells do not play a critical role during the effector phase of tumor rejection in MCMV-TRP2 vaccinated mice, MCMV-TRP2 induced long-term immune responses and long-term protection against tumor (Xu et al., 2013).
|
| References |
Xu et al., 2013: Xu G, Smith T, Grey F, Hill AB. Cytomegalovirus-based cancer vaccines expressing TRP2 induce rejection of melanoma in mice. Biochemical and biophysical research communications. 2013; 437(2); 287-291. [PubMed: 23811402].
|
|
